Your browser doesn't support javascript.
loading
PET-guided eBEACOPP treatment of advanced-stage Hodgkin lymphoma (HD18): follow-up analysis of an international, open-label, randomised, phase 3 trial.
Kreissl, Stefanie; Goergen, Helen; Buehnen, Ina; Kobe, Carsten; Moccia, Alden; Greil, Richard; Eichenauer, Dennis A; Zijlstra, Josée M; Markova, Jana; Meissner, Julia; Feuring-Buske, Michaela; Soekler, Martin; Beck, Hans-Joachim; Willenbacher, Wolfgang; Ludwig, Wolf-Dieter; Pabst, Thomas; Topp, Max S; Hitz, Felicitas; Bentz, Martin; Keller, Ulrich Bernd; Kühnhardt, Dagmar; Ostermann, Helmut; Hertenstein, Bernd; Aulitzky, Walter; Maschmeyer, Georg; Vieler, Tom; Eich, Hans; Baues, Christian; Stein, Harald; Fuchs, Michael; Diehl, Volker; Dietlein, Markus; Engert, Andreas; Borchmann, Peter.
Afiliación
  • Kreissl S; German Hodgkin Study Group, Department I of Internal Medicine and Center of Integrated Oncology Aachen, Bonn, Cologne, Düsseldorf, German Hodgkin Study Group, Faculty of Medicine and University Hospital of Cologne, University of Cologne, Cologne, Germany.
  • Goergen H; German Hodgkin Study Group, Department I of Internal Medicine and Center of Integrated Oncology Aachen, Bonn, Cologne, Düsseldorf, German Hodgkin Study Group, Faculty of Medicine and University Hospital of Cologne, University of Cologne, Cologne, Germany.
  • Buehnen I; German Hodgkin Study Group, Department I of Internal Medicine and Center of Integrated Oncology Aachen, Bonn, Cologne, Düsseldorf, German Hodgkin Study Group, Faculty of Medicine and University Hospital of Cologne, University of Cologne, Cologne, Germany.
  • Kobe C; Department of Nuclear Medicine, University Hospital of Cologne, University of Cologne, Cologne, Germany.
  • Moccia A; Department of Medical Oncology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland.
  • Greil R; IIIrd Medical Department, Paracelsus Medical University and Salzburg Cancer Research Institute, Salzburg, Austria; Salzburg Cancer Research Institute and Arbeitsgemeinschaft Medikamentöse Tumortherapie, Salzburg, Austria.
  • Eichenauer DA; German Hodgkin Study Group, Department I of Internal Medicine and Center of Integrated Oncology Aachen, Bonn, Cologne, Düsseldorf, German Hodgkin Study Group, Faculty of Medicine and University Hospital of Cologne, University of Cologne, Cologne, Germany.
  • Zijlstra JM; VU University Medical Center, Amsterdam, Netherlands.
  • Markova J; Department of Internal Medicine - Hematology, University Hospital Kralovske Vinohrady, Third Faculty of Medicine, Charles University, Prague, Czech Republic.
  • Meissner J; University of Heidelberg, Heidelberg, Germany.
  • Feuring-Buske M; Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany.
  • Soekler M; University of Tübingen, Tübingen, Germany.
  • Beck HJ; University Hospital Mainz, Mainz, Germany.
  • Willenbacher W; Salzburg Cancer Research Institute and Arbeitsgemeinschaft Medikamentöse Tumortherapie, Salzburg, Austria; Medical University Innsbruck, Internal Medicine V: Hematology & Oncology, Innsbruck, Austria; Oncotyrol, Center for Personalized Cancer Medicine, Innsbruck, Austria.
  • Ludwig WD; HELIOS Medical Center Berlin-Buch, Berlin, Germany.
  • Pabst T; Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland; Department of Medical Oncology, Inselspital Bern, Bern, Switzerland.
  • Topp MS; Medizinische Klinik und Poliklinik II, Universitätsklinikum Würzburg, Würzburg, Germany.
  • Hitz F; Cantonal Hospital of St Gallen, St Gallen, Switzerland.
  • Bentz M; Department of Internal Medicine III, Städtisches Klinikum Karlsruhe, Karlsruhe, Germany.
  • Keller UB; Medical Department, Division of Hematology and Oncology at Campus Benjamin Franklin, Berlin, Germany.
  • Kühnhardt D; Department of Hematology and Oncology, Charité University of Medicine, Berlin, Germany.
  • Ostermann H; Department of Hematology/Oncology, University Hospital of Munich, Munich, Germany.
  • Hertenstein B; Department of Internal Medicine I, Klinikum Bremen Mitte, Bremen, Germany.
  • Aulitzky W; Department of Haematology and Oncology, Robert Bosch Hospital, Stuttgart, Germany.
  • Maschmeyer G; Department of Haematology, Oncology and Palliative Care, Ernst von Bergmann Hospital, Potsdam, Germany.
  • Vieler T; Karl Lennert-Cancer Center, University Hospital Schleswig-Holstein, Kiel, Germany.
  • Eich H; Department of Radiotherapy, University Hospital of Münster, Münster, Germany.
  • Baues C; Department of Radiotherapy, University Hospital of Cologne, University of Cologne, Cologne, Germany.
  • Stein H; Berlin Reference Center for Lymphoma and Haematopathology, Berlin, Germany.
  • Fuchs M; German Hodgkin Study Group, Department I of Internal Medicine and Center of Integrated Oncology Aachen, Bonn, Cologne, Düsseldorf, German Hodgkin Study Group, Faculty of Medicine and University Hospital of Cologne, University of Cologne, Cologne, Germany.
  • Diehl V; German Hodgkin Study Group, Department I of Internal Medicine and Center of Integrated Oncology Aachen, Bonn, Cologne, Düsseldorf, German Hodgkin Study Group, Faculty of Medicine and University Hospital of Cologne, University of Cologne, Cologne, Germany.
  • Dietlein M; Department of Nuclear Medicine, University Hospital of Cologne, University of Cologne, Cologne, Germany.
  • Engert A; German Hodgkin Study Group, Department I of Internal Medicine and Center of Integrated Oncology Aachen, Bonn, Cologne, Düsseldorf, German Hodgkin Study Group, Faculty of Medicine and University Hospital of Cologne, University of Cologne, Cologne, Germany.
  • Borchmann P; German Hodgkin Study Group, Department I of Internal Medicine and Center of Integrated Oncology Aachen, Bonn, Cologne, Düsseldorf, German Hodgkin Study Group, Faculty of Medicine and University Hospital of Cologne, University of Cologne, Cologne, Germany. Electronic address: peter.borchmann@uk-koeln
Lancet Haematol ; 8(6): e398-e409, 2021 Jun.
Article en En | MEDLINE | ID: mdl-34048679
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Enfermedad de Hodgkin / Protocolos de Quimioterapia Combinada Antineoplásica Tipo de estudio: Clinical_trials / Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adolescent / Adult / Female / Humans / Middle aged Idioma: En Revista: Lancet Haematol Año: 2021 Tipo del documento: Article País de afiliación: Alemania
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Enfermedad de Hodgkin / Protocolos de Quimioterapia Combinada Antineoplásica Tipo de estudio: Clinical_trials / Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adolescent / Adult / Female / Humans / Middle aged Idioma: En Revista: Lancet Haematol Año: 2021 Tipo del documento: Article País de afiliación: Alemania